Regenxbio (RGNX) Short term Debt (2014)

Regenxbio's (RGNX) quarterly Short term Debt came in at $1.4 million in Q4 2014.

Regenxbio (RGNX) Short term Debt (2014) Analysis & Trends

Regenxbio's Short term Debt history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2014.

On a quarterly basis, Short term Debt changed N/A year-over-year to $1.4 million in Q4 2014; TTM through Dec 2014 was $1.4 million, a N/A change from a year earlier, with the FY2014 full-year figure at $1.4 million, changed N/A from the prior year.
Short term Debt was little changed at $1.4 million in Q4 2014 per RGNX's latest filing.
Across five years, Short term Debt topped out at $1.4 million in Q4 2014 and bottomed at $1.4 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Regenxbio	501.81 Mn	271.74 Mn	21.22 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2014	1.42 Mn